The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesVerena Hoffmann, Rüdiger Hehlmann, Perttu Koskenvesa et al.|Leukemia|2015Cited by 255
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Leukemia|2024Cited by 13
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 studyHjalmar Flygt, Henrik Hjorth‐Hansen, Stina Söderlund et al.|European Journal Of Haematology|2021Cited by 10
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Research Square|2023Cited by 2
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Leukemia|2024Cited by 0